XML 41 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

Segments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The table below summarizes the significant expense categories regularly reviewed by the Company’s president and chief executive officer, who is the Company’s chief operating decision maker (“CODM”), for the three months ended March 31, 2025 and 2024:
|  |  | Three Months Ended March 31,
|  |  |  |  | 2025 |  | 2024
Research and development expenses: |  |  |  |  |  |  |
Clinical trial expenses: |  |  |  |  |  |  |
IT-01 Study (Phase 1/2 Metastatic Cancers) |  |  |  |  | $ | — |  |  | $ | 53 |
INVINCIBLE-2 Study (Phase 2 Breast) |  |  |  |  | — |  |  | 103 |
INVINCIBLE-3 Study (Phase 3 Sarcoma) |  |  |  |  | 1,596 |  |  | 1,419 |
INVINCIBLE-4 Study (Phase 2 Breast) |  |  |  |  | 63 |  |  | — |
Clinical trial expenses |  |  |  |  | 1,659 |  |  | 1,575 |
Contract manufacturing |  |  |  |  | 24 |  |  | 214 |
Salaries and benefits related |  |  |  |  | 329 |  |  | 394 |
Consulting & Other(a) |  |  |  |  | 17 |  |  | 66 |
Stock-based compensation |  |  |  |  | 160 |  |  | 566 |
Research and development expenses |  |  |  |  | 2,189 |  |  | 2,815 |
General and administrative expenses: |  |  |  |  |  |  |
Salaries and benefits related |  |  |  |  | 230 |  |  | 324 |
Legal fees |  |  |  |  | 167 |  |  | 257 |
Audit fees |  |  |  |  | 77 |  |  | 115 |
Consulting |  |  |  |  | 196 |  |  | 173 |
Insurance |  |  |  |  | 157 |  |  | 286 |
Other(b) |  |  |  |  | 103 |  |  | 184 |
Stock-based compensation |  |  |  |  | 275 |  |  | 589 |
General and administrative expenses |  |  |  |  | 1,205 |  |  | 1,928 |
Loss from operations |  |  |  |  | (3,394) |  |  | (4,743) |
Other segment items(c) |  |  |  |  | 47 |  |  | 140 |
Net loss |  |  |  |  | $ | (3,347) |  |  | $ | (4,603) |
(a)Consulting & Other includes research and development consulting costs and travel-related costs. (b)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs. (c)Other segment items include interest income, interest expense, and foreign exchange gains and losses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration